Order Supplies

Cervical Health

Liquid based Cytology

Screenlink Healthcare are exclusive distributors of the ThinPrep® Pap Test in Ireland. The ThinPrep® Pap Test has shown to be significantly more effective than conventional Pap testing and is the global liquid based cytology market leader with more than 650 million tests performed so far to include in excess of 5 Million tests locally in Ireland over 20 years1.

Aptima® mRNA based HPV testing

The Aptima® HPV Assay is an in vitro nucleic acid amplification test for the qualitative detection of E6/E7 viral messenger RNA (mRNA) from 14 high-risk types of human papillomavirus (HPV) in cervical specimens.

The Aptima® HPV Assay is clinically proven to have the same excellent high sensitivity as DNA based tests along with a significantly improved specificity.  This results in minimising false negative results, while also significantly reducing false positives and unnecessary referrals to colposcopy2.

The Aptima® HPV 16 18/45 Genotyping assay provides a next generation genotyping option for HPV type 16 and HPV type 18 and 45 which together are associated with up to 94% of HPV related cervical adenocarcinomas3.

HPV Primary Screening

In 2017 The Health Information and Quality Authority (HIQA) carried out a health technology assessment which recommended that the Irish Screening Programme change the sequence of screening tests to primary HPV screening with liquid-based cytology follow-up testing4.

By offering the Aptima® HPV and ThinPrep® Pap Test together, Screenlink Healthcare offers a robust and proven supply chain for a total cervical health solution to include both primary HPV screening and follow up liquid based cytology to the benefit of Irish Women’s Health.

(1) Hologic Inc. Data on file.(2) Aptima HPV Assay package insert, UK English 14517-001.005.01, San Diego, CA; Hologic, 2015) (3 )De Sanjose et al, Human Papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross sectional worldwide study. Lancet Oncol 2010 (4) Health technology assessment of human papillomavirus testing as the primary screening method for prevention of cervical cancer, HIQA May 2017